Departament d'Estadística, Universitat de Barcelona, Spain.
J Neuroimmunol. 2012 Jul 15;248(1-2):23-31. doi: 10.1016/j.jneuroim.2012.04.008. Epub 2012 May 22.
Transcriptomics has emerged as a powerful approach for biomarker discovery. In the present review, the two main types of high throughput transcriptomic technologies - microarrays and next generation sequencing - that can be used to identify candidate biomarkers are briefly described. Microarrays, the mainstream technology of the last decade, have provided hundreds of valuable datasets in a wide variety of diseases including multiple sclerosis (MS), in which this approach has been used to disentangle different aspects of its complex pathogenesis. RNA-seq, the current next generation sequencing approach, is expected to provide similar power as microarrays but extending their capabilities to aspects up to now more difficult to analyse such as alternative splicing and discovery of novel transcripts.
转录组学已成为一种强大的生物标志物发现方法。在本综述中，简要描述了两种可用于识别候选生物标志物的高通量转录组学技术：微阵列和下一代测序。微阵列是过去十年的主流技术，在包括多发性硬化症（MS）在内的多种疾病中提供了数百个有价值的数据集，该方法已用于阐明其复杂发病机制的不同方面。RNA-seq 是目前的下一代测序方法，有望提供与微阵列类似的功能，但将其功能扩展到目前更难以分析的方面，如选择性剪接和新转录本的发现。
